Powered 500 · 2026POWEREDS. 095 of 500
After co-founding Kite Pharma and selling it to Gilead for $11.9 billion, Belldegrun is now building Allogene Therapeutics to make CAR T cell therapy available off-the-shelf — eliminating the patient-by-patient manufacturing that limits who can access it.
Arie Belldegrun is Founder and Executive Chairman of Allogene Therapeutics, a clinical-stage biotech developing allogeneic CAR T cell therapy for cancer.
He previously co-founded Kite Pharma, developer of the CAR T therapy Yescarta; Gilead Sciences acquired Kite in 2017 for $11.9 billion. A urologic oncologist by training, Belldegrun served as Chief of Urologic Oncology at UCLA.
Interview · In Pipeline
Sponsored placement
An invitation, extended to Powered readers.
Drive the Continental GT S.
Request a test driveBentley T&Cs apply
